NIKKEI 225
37,098.18 -981.52 (-2.58%) HANG SENG
16,246.34 -139.53 (-0.85%) CRUDE OIL
84.84 +2.11 (+2.55%) GOLD FUTURES
2,411.50 +13.50 (+0.56%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
49,425.32 -195.54 (-0.39%)
NovaBay Pharmaceuticals, Inc. (NBY)
After hours:
| Previous close | 0.0829 |
| Open | 0.0800 |
| Bid | 0.0800 x 1800 |
| Ask | 0.0809 x 1200 |
| Day's range | 0.0763 - 0.0859 |
| 52-week range | 0.0700 - 1.9500 |
| Volume | |
| Avg. volume | 3,480,945 |
| Market cap | 2.528M |
| Beta (5Y monthly) | 2.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.9600 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.60 |
- Business Wire
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
EMERYVILLE, Calif., April 17, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports preliminary net revenue for its eyecare and wound care business for the first quarter of 2024 of $2.6 million, a 13% increase from the first quarter of 2023. This increase was achieved with lower sales and marketing expenses, and is attributed primarily to social media marketing programs aimed at consumer sales of the Company’s lead product, Avenova Antimicrobial Lid & Lash Solution.
Insider MonkeyNovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q4 2023 Earnings Call Transcript
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q4 2023 Earnings Call Transcript March 26, 2024 NovaBay Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.95 EPS, expectations were $-0.3. NBY isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello and welcome to […]
- Thomson Reuters StreetEvents
Q4 2023 NovaBay Pharmaceuticals Inc Earnings Call
Q4 2023 NovaBay Pharmaceuticals Inc Earnings Call
